ArticleScientific reports2026
Interleukin-7 induces EMT to promote tumor growth and metastasis in NSCLC via Notch1/TGF-β pathway.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Interleukin 7 (IL‑7) regulates lymphangiogenesis and proliferation, inhibits apoptosis and autophagy in non‑small cell lung cancer (NSCLC). However, the role and detailed molecular mechanism of IL‑7 involved in NSCLC epithelial-to-mesenchymal transition (EMT) remain unknown. In this study, 119 cases of NSCLC tissue specimens were used to determine the expression levels and prognostic values of IL-7, IL-7R, E-cadherin and Vimentin. The CCK8, wound healing and transwell migration and invasion assays were employed to detect the NSCLC cell proliferation, migration and invasion, respectively. A subcutaneous tumor model and tail vein tumor injection in C57BL/6J mice were used to assess the role of IL-7 in vivo. Western blot, qRT-PCR and phalloidin staining assays were performed to investigate the molecular functions of IL-7. We find that IL‑7 down‑regulates E-cadherin, then up‑regulates N-cadherin, Vimentin and Snail1. In addition, IL-7 induces the expression of protein and mRNA of Notch1 and TGF-β. Inhibition of Notch1/TGF-β pathway reverses the proliferation, migration, invasiveness and EMT transition in NSCLC. In vivo, we find IL-7 promotes the growth of tumor and increases the number of lung metastasis nodules. E-cadherin is correlated with patients' survival and IL-7R is the strongest predictor of survival. In conclusion, IL-7 induces EMT to promote growth and metastasis NSCLC via the activation of Notch1/TGF-β pathway. IL-7 may be a potential target against human NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.